NeoStem (Nasdaq: NBS)

Facebooktwitterlinkedinmail

NeoStem (Nasdaq: NBS)

Investing – Small-Cap Market Intelligence • 4m 41s

Host Thomas Pfister, CFA interviews Robin Smith, M.D., CEO of NeoStem (Nasdaq: NBS), a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of cell-based therapeutics that prevent, treat, or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function

Facebooktwitterlinkedinmail